Illumina (NASDAQ:ILMN) announced Tuesday evening that the Food and Drug Administration had granted an Emergency Use Authorization (EUA) for COVIDSeq, a test that uses next-generation sequencing to detect SARS-CoV-2, the coronavirus that causes COVID-19.CEO Francis deSouza stated that the company and several of its customers are exploring the potential to use next-generation sequencing in high-volume screening to support individuals returning to work and school.